Neck dissections were done for all patients presenting with N3 nodal disease and for those patients with less than a complete response after induction chemotherapy
As recently as a couple years ago, back-to-back publications supported induction chemotherapy
plus chemo and radiation for head and neck cancer.
This trial showed that adding Induction Chemotherapy
to ChemoRadiotherapy increased failure-free survival while significantly increasing local control in patients with advanced unresectable head and neck cancer," said Fadlo Khuri, MD, Professor and Roberto Goizueta Chair of Hematology and Medical Oncology at Emory University, Atlanta, GA, USA.
Early response evaluation after induction chemotherapy
opens the door to a more individualized therapy in Barrett's cancer," added Dr.
Patients will receive either 2 cycles of induction chemotherapy
in combination with weekly doses of up to 16 mg/kg of HuMax-EGFr followed by 7 weekly doses of HuMax-EGFr in combination with chemo-radiation or 2 cycles of induction chemotherapy
followed by chemo-radiation alone.
Adult patients under 50 years of age (or under 55 years since 2004) were treated with two phases of induction chemotherapy
, and those who achieved complete remission (CR) were assigned to allogeneic transplant if a suitable sibling donor was available.
A serious concern with the induction arm was the failure to perform planned laryngectomy following a poor response to induction chemotherapy
in a large number of patients who were randomized to that group.
Validation studies currently are underway for tests to predict the success of induction chemotherapy
in patients with AML (both elderly and pediatric patients).
In an international, multicenter phase III study of 501 patients, induction chemotherapy
with docetaxel, cisplatin, and 5-fluorouracil (a combination known as TPF) was associated with a 30% reduction in mortality at 3 years, compared with standard induction chemotherapy
with cisplatin and 5-fluorouracil (known as PF), Dr.
in advanced head and neck tumors: Results of two randomized trials.
The trial is an open label, multi-center, randomized Phase 2 clinical trial to test the efficacy and safety of maintenance treatment with imetelstat in addition to standard of care versus standard of care alone in patients with advanced (stage IIIB or IV) NSCLC, who have not progressed after completing first-line induction chemotherapy
The drug has several approved indications in the United States: following induction chemotherapy
in patients with acute myelogenous leukemia; before and after transplantation of autologous peripheral blood progenitor cells; for myeloid reconstitution after autologous or allogenic bone marrow transplantation; and for bone marrow transplant failure or engraftment delay.